Novartis (NYSE:NVS) Posts Earnings Results, Beats Estimates By $0.18 EPS

Novartis (NYSE:NVS) released its quarterly earnings data on Friday. The company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.80 by $0.18, Zacks reports. Novartis had a return on equity of 34.80% and a net margin of 35.96%.

Novartis Trading Down 0.1 %

Shares of NYSE:NVS opened at $104.65 on Friday. Novartis has a 52-week low of $92.35 and a 52-week high of $120.92. The business has a 50-day moving average price of $100.09 and a 200-day moving average price of $108.50. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The stock has a market cap of $213.91 billion, a price-to-earnings ratio of 12.15, a PEG ratio of 1.49 and a beta of 0.57.

Wall Street Analysts Forecast Growth

NVS has been the topic of a number of recent research reports. StockNews.com downgraded shares of Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday. BMO Capital Markets lifted their price objective on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. HSBC cut shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Finally, Erste Group Bank reiterated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.